Juan J. Rodriguez, Oscar C. Munoz*, Mateo Porres-Aguilar and Debabrata Mukherjee Pages 23 - 29 ( 7 )
The coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus (SARS- CoV-2) is our latest pandemic and has turned out to be a global public health crisis. One of the special characteristics of this disease is that it may predispose patients to thrombotic disease both in the venous and arterial circulation. We review arterial and venous thromboembolic complications in patients with COVID-19, epidemiology, pathogenesis, hematologic biomarkers, and current antithrombotic strategies. Future perspectives and clinical trials are ongoing to determine the best thromboprophylaxis strategies in the hospitalized patients with severe COVID-19.
COVID-19, thrombosis, thromboembolism, venous thromboembolism, thromboprophylaxis, bleeding, stroke, myocardial infarction, pulmonary embolism.
Facultad de Medicina, Universidad Autonoma Bucaramanga, Bucaramanga, Department of Interventional Cardiology, Del Sol Medical Center, El Paso, TX 79925, Division of Adult Thrombosis Medicine, Centre of Excellence in Thrombosis and Anticoagulation Care (CETAC) at Jewish General Hospital, Department of Medicine, McGill University, Montreal, Quebec, Division of Cardiovascular Diseases, Department of Medicine, Texas Tech University Health Sciences Center at El Paso, El Paso, TX 79905